文献速递浆细胞疾病

达雷妥尤单抗单药治疗复发难治多发性骨髓瘤的真实世界研究:聚焦临床试验不适合患者及后续治疗

Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy.
PubMed 文献 · Br J Haematol · 2020-12-27

该多中心回顾性研究纳入107例接受达雷妥尤单抗单药治疗的复发难治多发性骨髓瘤患者,其中64例不符合既往GEN501和SIRIUS试验入组标准。对卡非佐米和/或来那度胺难治及中性粒细胞减少者缓解率更差,改良的试验不适合组PFS显著更差但后续治疗仍可获益。

要点

  • 对卡非佐米和/或来那度胺难治及中性粒细胞<1.0×10^9/L者ORR更差。

核心结论

  • 真实世界达雷妥尤单抗单药对RRMM显示有利疗效,后续治疗可能带来额外获益。
  • 与试验不适合对应的特征可能抵消达雷妥尤单抗单药的疗效。

研究设计与样本

  • 多中心回顾性研究,纳入107例接受达雷妥尤单抗单药治疗的复发难治多发性骨髓瘤患者。
  • 队列中64例为试验不适合患者,其特征不符合既往GEN501和SIRIUS试验入组标准。

主要发现

  • 对卡非佐米和/或来那度胺难治及中性粒细胞<1.0×10^9/L者ORR更差。

临床怎么用

  • 达雷妥尤单抗单药可用于RRMM,但需评估患者是否具有试验不适合特征以预判疗效。
  • 对卡非佐米和/或来那度胺难治及中性粒细胞减少者,达雷妥尤单抗单药缓解率可能更低。
  • 达雷妥尤单抗单药失败后,可考虑以泊马度胺为基础的治疗或卡非佐米-地塞米松方案。

局限性

  • 回顾性研究设计。
  • 样本量107例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world outcomes of daratumumab monotherapy (DM) for relapsed/refractory multiple myeloma (RRMM) have remained unclear. We conducted a multicentre retrospective study of 107 patients receiving DM for RRMM. The cohort included 64 trial-unfit patients whose characteristics could not meet inclusion criteria in two previous clinical trials (GEN501 and SIRIUS). The overall response rate (ORR), and median first and second progression-free survival (PFS1 and PFS2) and overall survival were 42·1%, and 3·6, 8·1 and 11·9 months, respectively. Refractoriness to carfilzomib and/or lenalidomide, and neutropenia (<1.0 × 109 /l) resulted in poorer ORRs. An Eastern Cooperative Oncology Group Performance Status of ≥3, neutropenia (<1.0 × 109 /l), thrombocytopenia (<75 × 109 /l), and renal failure (glomerular filtration rate of <20 ml/min/1·73 m2 ) were associated with poor PFS1 and PFS2 in respective univariate analysis. The modified trial-unfit group, based on the above factors, showed significantly negative impacts on PFS1 and PFS2 (hazard ratio 2·823 and 3·677, all P < 0·001) in multivariate analysis despite having a 34% ORR. Fatal infections occurred more often in the modified trial-unfit group than in the others (16·1% vs. 4·3%; P = 0·099). Despite failure of DM, subsequent therapy with pomalidomide-based therapy or carfilzomib-dexamethasone provided a 66·6% ORR. Real-world DM showed favourable efficacies for RRMM and, potentially, additional benefits with subsequent therapies. However, characteristics corresponding with trial-unfitness might offset the efficacy of DM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Park SS, Min Byun J, Yoon SS, et al. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. Br J Haematol. 2020. PMID: 33368165. doi:10.1111/bjh.17071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。